Constitutive expression of cathepsin K in the human intervertebral disc: new insight into disc extracellular matrix remodeling via cathepsin K and receptor activator of nuclear factor-κB ligand by Gruber, Helen E et al.
RESEARCH ARTICLE Open Access
Constitutive expression of cathepsin K in the
human intervertebral disc: new insight into disc
extracellular matrix remodeling via cathepsin K
and receptor activator of nuclear factor-B ligand
Helen E Gruber
1*, Jane A Ingram
1, Gretchen L Hoelscher
1, Natalia Zinchenko
1, H James Norton
2 and
Edward N Hanley Jr
1
Abstract
Introduction: Cathepsin K is a recently discovered cysteine protease which cleaves the triple helical domains of
type I to II collagen. It has been shown to be up-regulated in synovial tissue from osteoarthritic and rheumatoid
patients, and is a component in normal and nonarthritic cartilage, where it increases with aging. Studies on heart
valve development have recently shown that receptor activator of nuclear factor-B ligand (RANKL) acts during
valve remodeling to promote cathepsin K expression. Since extracellular matrix remodeling is a critical component
of disc structure and biomechanical function, we hypothesized that cathepsin K and RANKL may be present in the
human intervertebral disc.
Methods: Studies were performed following approval of the authors’ Human Subjects Institutional Review Board.
Six annulus specimens from healthier Thompson grade I to II discs, and 12 specimens from more degenerate
grade III to IV discs were utilized in microarray analysis of RANKL and cathepsin K gene expression.
Immunohistochemistry was also performed on 15 additional disc specimens to assess the presence of RANKL and
cathepsin K.
Results: Cathepsin K gene expression was significantly greater in more degenerated grade III to IV discs compared
to healthier grade I to II discs (P = 0.001). RANKL was also identified with immunohistochemistry and molecular
analyses. RANKL gene expression was also significantly greater in more degenerated discs compared to healthier
ones (P = 0.0001). A significant linear positive correlation was identified between expression of cathepsin K and
RANKL (r
2 = 92.2; P < 0.0001).
Conclusions: Extracellular matrix remodeling is a key element of disc biology. Our use of an appropriate antibody
and gene expression studies showed that cathepsin K is indeed present in the human intervertebral disc.
Immunolocalization and molecular analyses also confirmed that RANKL is present in the human disc. Expression of
RANKL was found to be significantly greater in more degenerated compared to healthier discs (P = 0.0001).
Cathepsin K gene expression levels showed a positive, significant correlation with RANKL expression. Based on
these data, we propose that cathepsin K plays a significant role in disc matrix remodeling and in matrix
degradation in the proinflammatory cytokine-rich microenvironment of the degenerating disc.
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Cathepsin K, discovered and isolated from a rabbit
osteoclast library in 1994 [1], is an interesting cysteine
protease which cleaves the triple helical domains of
types I to II collagen [1]. Research has shown that its
collagenolytic action requires that chondroitin or keratin
sulfate be bound to the protease [2]. Cathepsin K is pre-
sent in osteoclasts, human ovary, heart and skeletal
muscle, lung, placenta, testis, small intestine and colon
[3]. Studies have identified upregulation of cathepsin K
in fibroblast-like cells in synovial tissue of osteoarthritic
and rheumatoid patients [4-7]. A link to heightened
expression in the presence of IL-1ß or TNFa was also
shown by in vitro culture of fibroblasts derived from
rheumatoid patients in the work of Hou et al.[ 5 ] .I n
addition, an association with aging and increased cathe-
psin K levels has been suggested by Dejica et al.s i n c e
they found increased cathepsin K content in nonarthritic
cartilage from older compared to younger subjects [8].
Work by Ruettger et al. showed that cathepsin K is
regulated via activation of the classical protein kinase C
and p38 MAP kinase in articular chondrocytes [9].
Two interesting reports have shown spontaneous
development of synovitis and cartilage degeneration in
transgenic mice, which overexpress cathepsin K (trans-
genic UTU17 mice) [10,11]. In analysis of this model,
transgenic animals showed osteoarthritis and increased
levels of cathepsin K with aging. During growth and
aging, cathepsin K was found to be the most abundant
cysteine proteinase in them o u s ek n e ej o i n t ,w h e r e
cathepsin K was present near sites of matrix degenera-
tion and destruction in articular cartilage.
Cathepsin K is a recognized component of osteoclasts,
where it plays a central role in bone resorption [7].
RANKL (receptor activator of nuclear factor B ligand,
also known as TRANCE, TNFSF11, OPGL, and ODF) is
a member of the tumor necrosis factor family of signal-
ing molecules, which functions in promoting osteoclast
differentiation. RANKL, well known for its role in pro-
duction of extracellular matrix remodeling enzymes, is
one of the factors capable of inducing cathepsin K pro-
duction. This aspect of the biology of cathepsin K has
recently been studied by Combs and Yutzey in an analy-
sis of the regulation of heart valve development which
found that RANKL and cathepsin K are expressed by
endocardial cushion endothelial cells; RANKL acted dur-
ing valve remodeling to promote cathepsin K expression
[12].
Although there is not a large body of literature
addressing cathepsin K and its role in disc degeneration,
there are several previous interesting studies. The work
of Ariga et al. pointed to an association with endplate
separation and disorganization of the annulus in spinal
degenerative disorders [13]. Neidhart et al. found strong
expression of cathepsin K in a number of regions of the
spine in patients with ankylosing spondylitis [14]. Mwale
et al.h a v es t u d i e dt h ee f f e c to fac o l l a g e nt y p eI Ic o l -
lagen fragment (the 245-270 peptide) on disc cells [15].
This work showed that the addition of this peptide frag-
ment at levels of 1 μg/ml to cultured annulus cells
resulted in a significant increase in cathepsin K expres-
sion by one day of culture; expression levels decreased
over the following four days of culture and reached con-
trol levels. Nucleus cells exp o s e dt ot h i sf r a g m e n ta l s o
showed stimulated cathepsin K expression at one day of
exposure.
In the present study, we hypothesized that cathepsin K
might be an important component of matrix remodeling
overlooked to date in the intervertebral disc. We tested
this hypothesis by assessing gene expression of cathepsin
K and RANKL in human disc tissue, and also applied
immunohistochemistry analyses to disc tissues.
Materials and methods
Clinical study population
Experimental study of human disc specimens was
approved prospectively by the authors’ Human Subjects
Institutional Review Board at Carolinas Medical Center.
The need for informed consent was waived by the ethi-
cal board since disc tissue was removed as part of rou-
tine surgical practice. Scoring of disc degeneration
utilized the Thompson scoring system; this system
scores disc degeneration over the spectrum from a
healthy disc (Thompson grade I) to discs with advanced
degeneration (grade V, them o s ta d v a n c e ds t a g eo f
degeneration) [16]. Patient specimens were derived from
surgical disc procedures performed on individuals with
herniated discs and degenerative disc disease. Surgical
specimens were transported to the laboratory in sterile
tissue culture medium. Care was taken to remove all
g r a n u l a t i o nt i s s u ea n dt os a m p l eo n l yd i s ct i s s u e .N o n -
surgical control donor disc specimens were obtained via
the National Cancer Institute Cooperative Human Tis-
sue Network (CHTN); they were shipped overnight to
the laboratory in sterile tissue culture medium and pro-
cessed as described below. Specimen procurement from
the CHTN was included in our approved protocol by
our human subjects Institutional Review board.
Expression of cathepsin K and RANKL in vivo
Analysis of human disc tissue was carried out as pre-
viously described using laser capture microdissection
methods [17]. Total RNA was extracted from cells using
the TRIzol reagent (Gibco, Carlsbad, CA, USA), reverse
transcribed to double-stranded cDNA, subjected to two
rounds of transcription, and hybridized to the DNA
microarray in the Affymetrix Fluidics Station 400. Affy-
metrix human U133 X3P arrays were used. The GCOS
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Affymetrix, Santa Clara, CA, USA) was used for deter-
mining gene expression levels of RANKL and cathepsin
K (Affymetrix gene identifications AF053712.1 for
RANKL, and NM_000396.1 for cathepsin K).
Gene array data related to human disc tissue reported
here have been uploaded to the Gene Expression Omni-
bus (GEO) website [GEO:GSE23130] and may be
accessed at sample numbers GSM569830 - GSM569848.
Immunolocalization of RANKL
Disc specimens were fixed in 10% neutral buffered for-
malin for no longer than 24 hours and changed to 70%
ethanol. Undecalcified specimens were embedded in
paraffin and sections cut at 4 μm, collected on PLUS
slides (Allegiance, McGaw Park, IL, USA) and dried at
60°C. Sections were deparaffinized in xylene (Allegiance)
and rehydrated through graded alcohols (AAPER, Shel-
byville, KY, USA) to distilled water. Antigen retrieval
was performed using Dako Target Retrieval Solution,
pH 6.0 (Dako, Carpenteria, CA, USA) for 20 minutes at
95°C followed by cooling for 20 minutes. The remainder
of the procedure was performed using the Dako Auto-
stainer Plus (Dako) automated stainer. Endogenous per-
oxidase was blocked using 3% H202 (Humco, Texarcana,
TX, USA). Slides were incubated for one hour with
anti-RANKL (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) at a 1:50 dilution. Secondary antibody was 4
+Biotinylated Universal Goat Link (Biocare Medical,
Concord, CA, USA) for 10 minutes followed by 4+
streptavidin HRP Label (Biocare) for 10 minutes and
Vector NovaRed (Vector Laboratories, Burlingame, CA,
USA) for 5 minutes. Slides were removed from the stai-
ner, rinsed in water, counterstained with light green,
dehydrated, cleared and mounted with resinous mount-
ing media. Mouse IgG (Dako) was used as a negative
control. Human tonsil was utilized as a positive control.
Immunolocalization of cathepsin K
Following fixation and embedding as described above,
paraffin sections were cut at 4 μm, collected on PLUS
slides (Allegiance) and dried at 60°C. Sections were
deparaffinized in xylene (Allegiance) and rehydrated
through graded alcohols (AAPER) to distilled water. The
remainder of the procedure was performed using the
Dako Autostainer Plus (Dako) automated stainer. Endo-
genous peroxidase was blocked using 3% H202 (Humco).
Slides were incubated for one hour with anti-cathepsin
K (Abcam, Cambridge, MA, USA) at a 1:100 dilution.
M o u s eI g G( D a k o )w a su s e da san e g a t i v ec o n t r o l .A
secondary antibody was 4+Biotinylated Universal Goat
Link (Biocare Medical,) for 10 minutes followed by 4+
streptavidin HRP Label (Biocare) for 10 minutes and
DAB (Biocare)) for 5 minutes. Slides were removed
from the stainer, rinsed in water, counterstained with
light green, dehydrated, cleared and mounted with resi-
nous mounting media. Rat physeal tissue was used as a
positive control.
Statistical analyses
Standard statistical analyses were performed utilizing
InStat (GraphPad Software, Inc., San Diego, CA, USA).
Unpaired t-tests and linear regression analyses were per-
formed; means ± s.e.m. were calculated. P =0 . 0 5w a s
considered to be the level of significant.
Results
Molecular confirmation of in vivo expression of Cathepsin
k and RANKL expression in the human annulus
Six annulus specimens from healthier Thompson grade I
to II discs, and 13 specimens from more degenerate
grade III to IV discs were utilized in microarray analyses
of RANKL and cathepsin K gene expression. Demo-
graphic features for this study population are listed in
Table 1. As shown in Figure 1, cathepsin K expression
was significantly greater in more degenerate Thompson
grade III to IV discs than in healthier grade I to II discs
(P = 0.001). Statistical evaluation also found a positive,
significant correlation between the expression levels of
cathepsin K and those of RANKL (Figure 2; r
2 =9 2 . 2 ;P
< 0.0001). RANKL gene expression was also found to be
significantly greater in more degenerate Thompson
grade III to IV discs compared to healthier grade I to II
discs (Figure 3, P = 0.0001). Statistical analysis showed
that there was no relationship between age and either
cathepsin K or RANKL gene expression levels.
In vivo immunolocalization of cathepsin K and RANKL in
the human disc
Immunohistochemical studies were performed on speci-
mens derived from subjects whose demographic features
are described in Table 1. Cells in the outer annulus
showed strong immunolocalization of cathepsin K (Fig-
ure 4A). Inner annulus and nucleus regions showed that
some, but not all, cells were positive for cathepsin K
immunolocalization (Figure 4C, D). In the inner annu-
lus, cells in clusters also showed that not all cells were
positive for localization.
RANKL immunohistochemical analyses required anti-
gen retrieval during the localization procedure. Figure 5
shows cells positive for localization in the outer annulus
(Figure 5A), and in cells present in clusters in the inner
annulus (Figure 5B). Occasional positive cells were iden-
tified in the nucleus (data not shown).
Discussion
Improved understanding of the regulation of extracellu-
lar matrix turnover during normal homeostasis and
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topic in disc research [18]. As noted by Millward-Sadler
et al., matrix turnover has implications for the patho-
genesis of human disc degeneration [19]. Historically,
the matrix metalloproteinases, including MMP-1, -2, -3,
-7, -8, -9, -13, -19 and -28 [20-31], have been considered
the key players in disc matrix destruction during disc
degeneration.
In the present work we confirm that cathepsin K is
constitutively expressed in the human disc. Our analysis
showed that there was significantly greater expression of
cathepsin K in degenerated discs compared to healthier
ones (Figure 1). This finding suggests a role for cathe-
psin K in disc degeneration, and is in agreement with
the findings of Konttinen et al. that cathepsin K expres-
sion increased with the severity of osteoarthritis [6].
We now know that the degenerating disc has
increased expression of a number of important genes
related to the extracellular matrix [32] and proteogly-
cans [33], inflammatory cytokines, and matrix-degrading
agents, neurotrophins, and cytokines (for reviews and
studies see [26,33-41]). In vitro studies have been espe-
cially helpful in advancing our understanding of inflam-
matory cytokine production [42-45]. Hou et al.h a v e
shown that IL-1ß or TNFa in vitro stimulation of syno-
vial fibroblasts derived from rheumatoid or osteoar-
thritic subjects produced increased cathepsin K
expression. These two proinflammatory cytokines have
well-recognized roles in intervertebral disc degeneration
[46]. We hypothesize that in the cytokine rich milieu of
the degenerating disc cathepsin K plays a significant role
in disc matrix degeneration.
RANKL is recognized as a factor capable of inducing
cathepsin K production, and is known to be regulated
by IL-1ß and TNFa (see [7] for a recent review). In
addition to its acknowledged role in osteoclast develop-
ment and function [7], RANKL signaling activates a
number of pathways important in a number of cell
types including bone marrow stromal cells, fibroblasts,
mammary endothelial cells, epithelial cells, osteoblasts,
Table 1 Demographic features for specimens studied for
immunocytochemical localization of cathepsin K and
RANKL
Subject
number
Site Thompson
score
Age/
gender
Other
information
(cause of death)
Annulus specimens
1 L4 to 5 1.5 45/F CHTN (unknown)
1 L3 to 4 II 45/F CHTN (unknown)
2 L5 to S1 II 21/M Surgical
specimen
3 L4 to 5 2.5 40/M CHTN (MI)
4 L1 to 2 III 33/F CHTN (PE)
5 L4 to 5 III 33/F Surgical
specimen
6 L3 to 4 III 46/F Surgical
specimen
7 L5 to S1 III 53/M Surgical
specimen
8 L4 to 5 III 29/F Surgical
specimen
9 L2 to 3 III 54/M Surgical
specimen
4 L3 to 4 IV 33/F CHTN (PE)
10 L3 to 4 IV 59/F Surgical
specimen
10 L1 to 2 IV 59/F Surgical
specimen
10 L2 to 3 IV 59/F Surgical
specimen
11 L3 to 4 IV 78/M Surgical
specimen
12 L2 to 3 IV 56/F Surgical
specimen
13 L4 to 5 IV 39/F Surgical
specimen
14 L5 to S1 V 44/F Surgical
specimen
15 L5 to S1 V 39/F Surgical
specimen
Nucleus specimens
16 L4 to 5 3.5 68/F CHTN (stroke)
17 L3 to 4 V 69/M CHTN (MI)
18 L5 to S1 III 54/F CHTN (unknown)
19 L2 to 3;
L3 to 4
II 45/F CHTN (unknown)
20 L3 to 4;
T12 to L1
IV; 3.5 33/F CHTN (PE)
CHTN, Cooperative Human Tissue Network; F, female; age is presented in
years; L, Lumbar; M, male; MI, myocardial infarction; PE, pulmonary embolism;
S, sacral; T, thoracic.
Figure 1 Cathepsin K expression and stages of disc
degeneration. Cathepsin K gene expression was significantly
greater in annulus tissue from more degenerated discs than in
healthier discs (P = 0.001). Data are means ± s.e.m.
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In 2009, Mackiewicz et al. showed the immunohisto-
chemical presence of RANKL in human annulus tissue
[49].
In the present work, we identified significantly
increased RANKL gene expression in more degenerated
discs compared to healthier discs (Figure 3). Our ana-
lyses of gene expression data from disc tissue also
showed a significant, positive linear relationship between
cathepsin K and RANKL expression which accounted
for a high proportion of the variability in this relation-
ship (92.2%, Figure 2). This finding is also consistent
with regulation of cathepsin K expression during disc
degeneration; we note, however, that future mechanistic
studies should be undertaken to further explore this
control mechanism. Other aspects of RANKL function
in the disc merit future studies to determine whether it
acts to inhibit proliferation and to induce apoptosis as
was seen by McGonigle et al. in endothelial cells [50].
It should be noted that the present analyses utilized
only annulus cells in the microarray expression studies;
we currently are adding nucleus specimens so that
future work can explore expression patterns in nucleus
cells as well as the annulus. We look forward to data
from other disc research labs on this topic. Important
future studies should include in vivo analyses to deter-
mine the exact relationship between cathepsin K and
RANKL expression, correlations of cathepsin K levels to
collagen fragments within the disc (as pioneered in the
important work of Neidart et al. [14] and Mwale et al.
[15], and expanded in vitro studies with annulus and
nucleus cells.
In closing, a note should also be made concerning the
current clinical interest in development of cathepsin K
inhibitors because of their ability to inhibit bone resorp-
tion [3,7,51,52]. As we continue to move towards the
application of biologic therapies for human disc degen-
eration, it may be efficacious to consider inclusion of
selective, specific approaches to inhibit cathepsin K.
Yasuca et al. reported in 2005 that some cathepsin K
inhibitors are now in clinical trials for osteoporosis ther-
apy, and noted that cathepsin K is a preferable drug tar-
get for non-inflammatory osteoarthritis with positive
pre-clinical data [3].
Figure 2 Relationship between RANKL expression and
cathepsin K expression. A significant, positive correlation was
present between gene expression levels of RANKL and cathepsin K
(r
2 = 92.2; P < 0.0001). (Dashed line shows the 95% confidence
interval for the correlation).
Figure 3 RANKL expression and stages of disc degeneration.
RANKL gene expression was significantly greater in annulus tissue
from more degenerated discs than in healthier discs (P = 0.0001).
Data are means ± s.e.m.
Figure 4 Representative images showing immunohistochemical
localization of cathepsin K in the human disc.
Immunohistochemical localization (black localization product) shows
the presence of cathepsin K in the outer annulus (Figure 4A). Figure
4B shows an adjacent negative control section from the outer
annulus. Within the inner annulus (Figure 4C) and nucleus (Figure
4D), both positive and negative cells were present. (Scale bar for
Figure 4A is the same as that shown for Figure 4B).
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Collectively, our results demonstrate the constitutive
expression of cathepsin K and RANKL within human
intervertebral disc tissue. Gene expression studies
showed that both cathepsin K and RANKL expression
levels are significantly greater in annulus tissue from
more degenerated discs compared to levels in present
healthier discs (P = 0.001 and 0.0001, respectively). A
positive significant correlation was identified between
expression levels of cathepsin K and RANKL (r
2 = 92.2; P
< 0.0001). Based on these data, we suggest that cathepsin
K may play a significant role in disc matrix remodeling
and in matrix degradation in the proinflammatory cyto-
kine-rich microenvironment of the degenerating disc.
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